摘要:
A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B). According to the method of the present invention, the level of a progressive risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention in the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk.
摘要翻译:一种确定青光眼风险的存在或不存在的方法,包括以下步骤:在位于碱基序列的第31位的单核苷酸多态性的体外检测等位基因和/或基因型, 其中所述碱基序列是选自SEQ ID NO:203至752所示的碱基序列或其互补序列的至少一种碱基序列(步骤A),并比较检测到的等位基因和/或基因型 在SEQ ID NO:203〜752(步骤B)所示的碱基序列中具有含有高风险等位基因的等位基因和/或基因型中的至少一种的步骤A。 根据本发明的方法,可以通过分析样品中本发明的单核苷酸多态性的等位基因或基因型来确定样品供体中青光眼进行性风险的水平,使得样品供体可以 采取预防措施的青光眼,或者可以根据这种风险接受适当的治疗。
摘要:
A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B). According to the method of the present invention, the level of a progressive risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention in the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk.
摘要翻译:一种确定青光眼风险的存在或不存在的方法,包括以下步骤:在位于碱基序列的第31位的单核苷酸多态性的体外检测等位基因和/或基因型, 其中所述碱基序列是选自SEQ ID NO:203至752所示的碱基序列或其互补序列的至少一种碱基序列(步骤A),并比较检测到的等位基因和/或基因型 在SEQ ID NO:203〜752(步骤B)所示的碱基序列中具有含有高风险等位基因的等位基因和/或基因型中的至少一种的步骤A。 根据本发明的方法,可以通过分析样品中本发明的单核苷酸多态性的等位基因或基因型来确定样品供体中青光眼进行性风险的水平,使得样品供体可以 采取预防措施的青光眼,或者可以根据这种风险接受适当的治疗。
摘要:
An object of the present invention is to provide a protective agent for a neuronal cell. The protective agent for a neuronal cell according to the present invention contains a compound represented by the following general formula [I] or a salt thereof as an active ingredient. In the formula, R1, R2 and R3 are the same or different and represent a hydrogen atom or an alkyl group, or R1 and R3 may be joined together to form a ring having one or more double bonds.
摘要:
A key switch includes an actuator for rotatably engaging the upper end of one of lever members, which constitute a cross-linked member, therewith and slidably engaging the upper end of the other lever member therewith. After the cross-linked member engaged with the actuator at its upper end is mounted on a membrane switch, the bottom of a key top is retained on the actuator by a simple means a as press fitting. This simplifies a molding die for the key top and facilitates an operation of attaching the key top.
摘要:
A keyboard apparatus permits easier installation of slide retaining pins to a retaining portion and prevents intrusion of dust into the keyboard apparatus from the back surface of a supporting substrate thereof. A first retaining portion has a narrow area and a wide area, and slide retaining pins are latched in the wide area. A dust-proof sheet is provided on the bottom surface of a supporting substrate to cover through holes in the supporting substrate, the through holes resulting from the formation of the first retaining portion and second retaining portions.
摘要:
A method of determining the presence or the absence of a glaucoma risk by detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism, comparing the allele and/or the genotype detected with at least one of an allele and/or a genotype with a high-risk allele, wherein the presence of a glaucoma risk is determined in a case where the allele detected is the high-risk allele, or the presence of a glaucoma risk is determined in a case where the genotype detected is a homozygote of the genotype comprising the high-risk allele or a heterozygote when the high-risk allele complies with a dominant genetic model, or the presence of a glaucoma risk is determined in a case where the genotype detected is a homozygote of the genotype comprising the high-risk allele when the high-risk allele complies with a recessive genetic model.
摘要:
A method for preventing or treating an optic nerve disorder, inhibiting retinal nerve cell death or recovering a neurofilament light chain expression level by administering to a patient a pharmacologically effective amount of at least one of the compound represented by the following formula (1): wherein R1 is a hydrogen atom or a lower alkyl group R2 is a hydrogen atom or a lower alkyl group; R1 and R2 may be joined to each other to form an aziridine ring, an azetidine ring, a pyrrolidine ring, a piperidine ring or an azepane ring; and R3 is a carboxyl group or an ester thereof or an amide thereof; or a salt thereof.
摘要翻译:一种通过向患者施用药理学有效量的由下式(1)表示的化合物中的至少一种的方法,其用于预防或治疗视神经障碍,抑制视网膜神经细胞死亡或恢复神经丝轻链表达水平:其中 R1是氢原子或低级烷基R2是氢原子或低级烷基; R 1和R 2可以彼此连接形成氮丙啶环,氮杂环丁烷环,吡咯烷环,哌啶环或氮杂环。 并且R 3是羧基或其酯或其酰胺; 或其盐。
摘要:
A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 514 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 514 (step B). According to the method of the present invention, the level of an onset risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention on the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk.
摘要翻译:一种确定青光眼风险的存在或不存在的方法,包括以下步骤:在位于碱基序列的第31位的单核苷酸多态性的体外检测等位基因和/或基因型, 其中所述碱基序列是选自SEQ ID NO:203至514所示的碱基序列或其互补序列的至少一种碱基序列(步骤A),并比较检测到的等位基因和/或基因型 具有SEQ ID NO:203〜514(步骤B)所示的碱基序列中的含有高风险等位基因的等位基因和/或基因型中的至少一种的步骤A。 根据本发明的方法,可以通过对样品中的本发明中的单核苷酸多态性的等位基因或基因型进行分析来确定样品供体中的青光眼的发病风险水平,从而样品供体可以 采取预防措施的青光眼,或者可以根据这种风险接受适当的治疗。
摘要:
A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: ##STR1## wherein A is a vinylene group or the like, R.sup.1 is an aryloxyalkyl group or the like, R.sup.2 and R.sup.3 are hydrogen atoms or the like, and Z is OR.sup.4 (wherein OR.sup.4 is a hydrogen atom or an alkyl group) or the like.